Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Goldenberg

Showing results (131-140 of 296) with videos related to

Pageof 30
Sort By:
American Journal of Surgery|June 5, 2012
Anti-class II -DR humanized monoclonal antibody, IMMU-114, blocks allogeneic immune responseKyung Hwa Park, Tokihiko Sawada, Toru Murakami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapyAlice P Taylor, Louis Osorio, Russell Craig, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 26, 2002
Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/non-tumor localization ratiosSerengulam V Govindan, Gary L Griffiths, Rosana B Michel, et al.
Bioconjugate Chemistry|September 10, 2009
A new method to produce monoPEGylated dimeric cytokines shown with human interferon-α2bChien-Hsing Chang, Edmund A Rossi, Thomas M Cardillo, et al.
Cancer Research|July 3, 2008
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibodyRobert M Sharkey, Habibe Karacay, Samuel Litwin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Epratuzumab: targeting B-cell malignancies through CD22Morton Coleman, David M Goldenberg, Abby B Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2005
Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibodyRhona Stein, Serengulam V Govindan, Marianne Hayes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
CD74 is expressed by multiple myeloma and is a promising target for therapyJack D Burton, Scott Ely, Praveen K Reddy, et al.
Advances in Experimental Medicine and Biology|October 18, 2003
Tumor pO2 assessments in human xenograft tumors measured by EPR oximetry: location of paramagnetic materialsJulia A O'Hara, Rosalyn D Blumenthal, Oleg Y Grinberg, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 16, 2006
Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic originManuel J Koppe, Wim J G Oyen, Robert P Bleichrodt, et al.
Pageof 30

Showing results (131-140 of 296) with videos related to

Sort By:
Pageof 30
American Journal of Surgery|June 5, 2012
Anti-class II -DR humanized monoclonal antibody, IMMU-114, blocks allogeneic immune responseKyung Hwa Park, Tokihiko Sawada, Toru Murakami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapyAlice P Taylor, Louis Osorio, Russell Craig, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 26, 2002
Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/non-tumor localization ratiosSerengulam V Govindan, Gary L Griffiths, Rosana B Michel, et al.
Bioconjugate Chemistry|September 10, 2009
A new method to produce monoPEGylated dimeric cytokines shown with human interferon-α2bChien-Hsing Chang, Edmund A Rossi, Thomas M Cardillo, et al.
Cancer Research|July 3, 2008
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibodyRobert M Sharkey, Habibe Karacay, Samuel Litwin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Epratuzumab: targeting B-cell malignancies through CD22Morton Coleman, David M Goldenberg, Abby B Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2005
Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibodyRhona Stein, Serengulam V Govindan, Marianne Hayes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
CD74 is expressed by multiple myeloma and is a promising target for therapyJack D Burton, Scott Ely, Praveen K Reddy, et al.
Advances in Experimental Medicine and Biology|October 18, 2003
Tumor pO2 assessments in human xenograft tumors measured by EPR oximetry: location of paramagnetic materialsJulia A O'Hara, Rosalyn D Blumenthal, Oleg Y Grinberg, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 16, 2006
Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic originManuel J Koppe, Wim J G Oyen, Robert P Bleichrodt, et al.
Pageof 30